Medexus Pharmaceuticals Inc.
MEDXF
$2.24
-$0.031-1.37%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 24.75M | 29.99M | 26.30M | 27.28M | 25.96M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 24.75M | 29.99M | 26.30M | 27.28M | 25.96M |
| Cost of Revenue | 9.96M | 13.11M | 10.66M | 11.10M | 11.27M |
| Gross Profit | 14.79M | 16.89M | 15.65M | 16.19M | 14.69M |
| SG&A Expenses | 12.17M | 10.97M | 9.69M | 10.35M | 10.37M |
| Depreciation & Amortization | 2.44M | 1.76M | 1.58M | 1.41M | 1.45M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.04M | 26.21M | 22.20M | 22.95M | 23.14M |
| Operating Income | -290.00K | 3.78M | 4.10M | 4.33M | 2.83M |
| Income Before Tax | -759.00K | 880.00K | -581.00K | 1.90M | 990.00K |
| Income Tax Expenses | -206.00K | 147.00K | -691.00K | -57.00K | 228.00K |
| Earnings from Continuing Operations | -553.00K | 733.00K | 110.00K | 1.96M | 762.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -553.00K | 733.00K | 110.00K | 1.96M | 762.00K |
| EBIT | -290.00K | 3.78M | 4.10M | 4.33M | 2.83M |
| EBITDA | 2.10M | 5.54M | 5.68M | 5.70M | 4.12M |
| EPS Basic | -0.02 | 0.03 | 0.00 | 0.08 | 0.03 |
| Normalized Basic EPS | 0.00 | 0.02 | 0.05 | 0.06 | 0.08 |
| EPS Diluted | -0.02 | 0.03 | 0.00 | 0.08 | 0.03 |
| Normalized Diluted EPS | 0.00 | 0.02 | 0.05 | 0.06 | 0.08 |
| Average Basic Shares Outstanding | 29.60M | 24.68M | 24.55M | 24.46M | 24.45M |
| Average Diluted Shares Outstanding | 29.60M | 24.68M | 24.55M | 24.46M | 24.45M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |